Bridge Medicines, a NYC-based drug discovery company focused on advancing promising early technologies from concept to clinic, raised additional funding of $10m.
The company intends to use the funds to advance its current pipeline of products as well as expand with additional in-licensed technologies.
Launched in 2016 by Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceutical Company Ltd., in partnership with Deerfield Management Company and Bay City Capital, Bridge Medicines is currently developing novel inhibitors of ENL-YEATS for the treatment of acute leukemias such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. In addition, the company is in discussions on and evaluating several other in-licensing opportunities from our institutional partners.
Bridge is led by Bill Polvino, MD, Chief Executive Officer.